0

Successful Treatment of Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate: A Case Series

Margarita Arboleda, Santiago Barrantes, Luz Yaned Úsuga, Sara María Robledo

Rev Soc Bras Med Trop. 2019 May 16;52:e20180211.

PMID: 31141044

Abstract:

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate: seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP6284408-A Meglumine Meglumine 6284-40-8 Price
qrcode